Waltham, Massachusetts, October 6, 2026 ( GLOBE NEWSWIRE ) – Repligen Corporation (Nasdaq: RGEN, hereinafter referred to as “Repligen” or “the Company”) announced today that it has completed the acquisition of BioLife Solutions, Inc (Nasdaq: BLFS, hereinafter referred to as “BioLife”). BioLife is a leading company in the cell and gene therapy market, developing and supplying cell processing tools and services.

Repligen, President and CEO, Olivier Loeillot said: "We are very pleased to welcome the members of the BioLife team to Repligen. BioLife's highly differentiated product portfolio has expanded our presence in the rapidly growing cell therapy market, adding a new consumables business that is deeply embedded, has a higher gross margin, and generates attractive recurring revenue. After the merger, we will be better equipped to support customers through key stages of the cell therapy workflow and help advance the development and commercialization of next-generation therapies. Over the past few months, our teams have worked closely together to develop a thorough integration plan; we are even more excited about the strategic rationale for combining the two companies and the ability to create value for patients, customers, and shareholders."

BioLife's products are deeply integrated into the cell therapy workflow and complement Repligen's existing related businesses to a high degree. BioLife offers a differentiated portfolio of biological preservation media products represented by CryoStor ®, which supports 18 commercially approved therapies and most of the projects in US commercially sponsored cell therapy trials. As a merged commercial team, BioLife will benefit from Repligen's broader global coverage, especially in the Asia-Pacific region; whereas Repligen will benefit from BioLife's reliable customer relationships.

In relation to this transaction, BioLife shareholders will receive $11.25 in cash per share, as well as 0.1442 shares of Repligen common stock. Any fractional shares of Repligen common stock will be replaced by cash.

Repligen indicates that more details regarding the expected impact of this transaction pair Repligen on the financial outlook for 2026 will be provided during the upcoming third-quarter 2026 earnings conference call.

Consultant

Perella Weinberg Partners LP and Goldman Sachs as well as Co serve as the financial advisors for Repligen, while Goodwin Procter LLP acts as its legal counsel. Centerview Partners and LLC act as the financial advisors for BioLife, with K& L Gates LLP serving as its legal counsel.

About Repligen Corporation

Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocess technologies and systems to improve the efficiency of biopharmaceutical manufacturing processes. The company is committed to "stimulating advancements in bioprocessing" for its clients, who are primarily global biopharmaceutical drug developers and contract development and production organizations (CDMO). Its key areas of expertise include filtration and fluid management, chromatography, process analysis, and proteins. The company's headquarters are located in Waltham, Massachusetts, with most of its manufacturing facilities in the United States, as well as significant sites in Estonia, Germany, Ireland, the Netherlands, and Sweden. For more information, visit the company's website at www.repligen.com, and follow the company on LinkedIn.

Forward-looking Statements

This press release may contain forward-looking statements as defined by the U.S. Federal Securities Laws. Investors should note that statements in this press release that are not strictly historical facts include, but are not limited to, statements regarding expected transactional earnings and Repligen's ability to achieve such earnings; statements regarding the expected financial impact of the transaction on Repligen; performance expectations for Repligen after the completion of the transaction; and opinions and expectations regarding the cell therapy industry (including its growth) and BioLife's position as a leader in highly differentiated cell processing tools. Words such as "believes," "expects," "may," "will," "should," "seek," or "can" and their variations, as well as similar expressions, are intended to identify such forward-looking statements. Such forward-looking statements are subject to various risks and uncertainties that could cause actual results to differ significantly from those anticipated, including risks discussed from time to time in the company's filings with the U.S. Securities and Exchange Commission. Except as required by law, the company explicitly disclaims any responsibility to update any forward-looking statements.

Repligen Contact Person

Jacob Johnson